✦ LIBER ✦

Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients

✍ Scribed by Luisa Zanette; Massimo Zucchetti; Andrea Freshi; Domenico Erranti; Umberto Tirelli; Maurizio D'Incalci

Publisher: Springer
Year: 1990
Tongue: English
Weight: 374 KB
Volume: 25
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00686057

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Uridine pharmacokinetics in cancer patie

Uridine pharmacokinetics in cancer patients

✍ Thomas C. K. Chan; Maurie Markman; Craig E. Pfeifle; Raymond Taetle; Ian Abramso 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 408 KB

The availability of uridine can alter the sensitivity of tumor cells to antimetabolites such as N-phosphonacetyl-L-aspartic acid (PALA) and acivicin by virtue of the cell's ability to salvage preformed metabolites from its environment. We investigated the pharmacokinetics of physiologically relevant

Pharmacokinetics of tauromustine in canc

Pharmacokinetics of tauromustine in cancer patients

✍ P. O. Gunnarsson; J. Vibe-Petersen; J. S. Macpherson; P. S. Warrington; J. Polac 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 408 KB

Oral 4-demethoxydaunorubicin (idarubicin

Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial

✍ Howard S. Hochster; Michael D. Green; Ronald H. Blum; James C. Wernz; James L. S 📂 Article 📅 1986 🏛 Springer US 🌐 English ⚖ 258 KB

Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxydaunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to th

Pharmacokinetics of intravenous ATP in c

Pharmacokinetics of intravenous ATP in cancer patients

✍ H. J. Agteresch; P. C. Dagnelie; T. Rietveld; J. W. O. van den Berg; A. H. J. Da 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 130 KB

Biliary excretion and pharmacokinetics o

Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients

✍ Carlo M. Camaggi; Elena Strocchi; Raffaella Comparsi; Fabio Testoni; Bruna Angel 📂 Article 📅 1986 🏛 Springer 🌐 English ⚖ 380 KB

A phase II study of oral idarubicin (4-d

A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer

✍ Nicholas S. A. Stuart; Michael H. Cullen; Terrence J. Priestman; George R. P. Bl 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 352 KB

Idarubicin (4-demethoxydaunorubicin: DMDNR) is an orally active analogue of daunorubicin that has shown promising activity in animal and early clinical studies. We gave idarubicin in a phase II study to patients with advanced breast cancer unresponsive to hormonal manipulation and in some cases to s